PAPILLARY RENAL CELL CARCINOMA
Clinical trials for PAPILLARY RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PAPILLARY RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PAPILLARY RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack shows promise for rare bladder and kidney cancers
Disease control Recruiting nowThis study tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in people with rare genitourinary cancers that have spread. The goal is to see if this mix can shrink tumors or stop them from growing. About 314 adults with these rare cancers will take part. T…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:59 UTC
-
New drug cocktail aims to shrink Hard-to-Treat kidney tumors
Disease control Recruiting nowThis study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare inherited form (HLRCC) or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood supply, …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Scientists track Cancer's food choices in real time
Knowledge-focused Recruiting nowThis study looks at how kidney and bladder cancers use nutrients like sugar and fat to grow. About 600 adults having surgery or a biopsy will receive a special nutrient tracer through an IV. Blood and tissue samples are then analyzed to see how the cancer uses these fuels. Partic…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC
-
Researchers dig into past records to see if older drugs help rare kidney cancer
Knowledge-focused Recruiting nowThis study reviews medical records of 150 Chinese adults with advanced papillary kidney cancer who received sunitinib or sorafenib as their first treatment. The goal is to see how long patients live without their cancer getting worse. Since this is a retrospective study, it does …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 12, 2026 13:41 UTC